Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3025–3048 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Overall Health
Interventions: Placebo Control, Active Product; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Rheumatoid Arthritis
Interventions: adalimumab, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 48
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 44 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 35
States / cities: Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Cilostazol 100 MG, Placebo; Drug · Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Fecal Incontinence
Interventions: Education, Fiber supplements, Laxatives or anti-diarrheals, Pelvic floor muscle exercises, Tips on how to prevent fecal incontinence, Daily diary, Protective pads or garments; Other · Dietary Supplement · Drug + 1 more
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Smoking, Tobacco Withdrawal
Interventions: Galantamine, IV Nicotine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Post-traumatic Stress Disorder, Major Depressive Disorder
Interventions: pregnenolone, placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Traumatic Brain Injury
Interventions: PNT001, %5 dextrose for infusion; Biological
Lead sponsor: Pinteon Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: ADHD
Interventions: CLONICEL (clonidine HCl sustained release), Placebo; Drug
Lead sponsor: Addrenex Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 23
States / cities: Little Rock, Arkansas • El Centro, California • Irvine, California + 18 more

Conditions: Post-Treatment Lyme Disease Syndrome
Interventions: Ceftriaxone treatment, Placebo; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Uncontrolled Hypertension
Interventions: CIN-107, Placebo; Drug
Lead sponsor: CinCor Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 63
States / cities: Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more

Conditions: Mild to Moderate Alzheimer's Disease
Interventions: ORY-2001 Low dose, ORY-2001 High dose, Placebo; Drug
Lead sponsor: Oryzon Genomics S.A.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Wellington, Florida • Columbus, Georgia • Princeton, New Jersey + 1 more

Conditions: Brain Concussion
Interventions: MedX Health Console model 1100, MedX Health Console model 1100-placebo; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 11 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts • Waltham, Massachusetts

Conditions: Hypertension
Interventions: placebo, PF-00489791; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Los Angeles, California • Santa Ana, California • Tustin, California + 15 more

Conditions: Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
Interventions: doxepin hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 120
States / cities: Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more

Conditions: Hidradenitis Suppurativa
Interventions: Risankizumab, Placebo for risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Hot Springs, Arkansas • Bakersfield, California • Los Angeles, California + 17 more

Conditions: Influenza
Interventions: 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo; Drug
Lead sponsor: Biota Scientific Management Pty Ltd; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 70
States / cities: Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more

Conditions: Post-Herpetic Neuralgia
Interventions: pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 11 more

Conditions: Healthy Volunteers
Interventions: Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cocaine Dependence
Interventions: D-serine, Cognitive Behavioral Therapy, Placebo; Drug · Behavioral
Lead sponsor: Theresa Winhusen; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pelvic Pain, IUD
Interventions: Ibuprofen, Placebos; Drug
Lead sponsor: Orlando VA Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: HIV/AIDS
Interventions: eOD-GT8 60mer + AS01B/ DPBS sucrose/IM, DPBS Sucrose; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Seattle, Washington

Conditions: Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating, Pain, Splitting
Interventions: JNJ-42160443, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 17
States / cities: Birmingham, Alabama • Tucson, Arizona • Laguna Hills, California + 14 more

Conditions: Asthma
Interventions: Lebrikizumab, Placebo, Standard of Care; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 16
States / cities: Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more

Search by objective public record fields.

Radicle Health 25: A Study of Health and Wellness Products on Overall Health

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

Educational-Medical-Behavioral Treatment of Fecal Incontinence

Galantamine Effects on Nicotine Responses in Smokers

Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD

Ceftriaxone for Post-Treatment Lyme Disease

A Study of CIN-107 in Patients With Uncontrolled Hypertension

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

LED Therapy for the Treatment of Concussive Brain Injury

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

TAK-071 Scopolamine-Induced Cognitive Impairment Study

D-Serine for Cocaine Dependence Pilot

Multi-dose Ibuprofen Prophylaxis for IUD-insertion

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication